Cost-Effectiveness of Expanded HIV Screening Among Adult Population in Italy
Author(s)
Bini C1, Mennini FS1, Rotundo M2, Marcellusi A1, Antinori A3, Sarmati L4, Andreoni M5, Paoletti M1
1Economic Evaluation and HTA (EEHTA CEIS), Department of Economics and Finance, Faculty of Economics, University of Rome “Tor Vergata”, Rome, Italy, 2Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Roma, RM, Italy, 3Istituto Nazionale per le Malattie Infettive “Lazzaro Spallanzani” IRCCS, Rome, Rome, Italy, 4University of Rome “Tor Vergata”, Rome, Italy, 5University of Rome, Rome, Italy
OBJECTIVES : The global targets set out by the Joint United Nations Programme on HIV/AIDS (UNAIDS) for 2020 are to diagnose 90% of all HIV-positive people, provide antiretroviral therapy for 90% of those diagnosed, and achieve viral suppression for 90% of those treated (known as 90-90-90 targets). In Italy, there is no uniform HIV screening strategy across the country. Our study aimed to assess the cost-effectiveness of expanded HIV screening among adult population (25-50 years). METHODS : A decision tree was combined with a previously published Markov model for evaluate the management of HIV-infected patients in Italy. The model was informed by epidemiological and cost estimates taken from different sources (literature and real-world data). The cohort of new HIV diagnosed patients effectively linked to care in Italy (2,847 patients) was followed over a 30-year time horizon evaluating different scenarios for new HIV diagnoses due to the expanded HIV screening. The analysis was conducted from the National Health Service perspective and both costs and QALYs were discounted at an annual rate of 3%. Deterministic and probabilistic sensitivity analysis were conducted to evaluate parameter uncertainty. RESULTS : Our preliminary analysis showed that with an increase of 10% of new HIV linked to care patients, HIV screening strategy resulted in an increment of about 2,466 QALYs and in an increment of about € 73.8 million compared to the status quo from the Italian NHS perspective. The ICER was equal to € 29,943/QALY. Probabilistic sensitivity analysis confirmed that the expanded HIV screening would be cost-effective for > 51% of simulations at a minimum willingness-to-pay threshold of € 30,000 per QALY gained. CONCLUSIONS : In Italy there is an urgent need to apply HIV screening strategies to increase awareness of the risks of the disease. Our analysis indicates that the expanded HIV screening in adult population would be cost-effective.
Conference/Value in Health Info
2020-11, ISPOR Europe 2020, Milan, Italy
Value in Health, Volume 23, Issue S2 (December 2020)
Code
PIN38
Topic
Clinical Outcomes, Economic Evaluation, Epidemiology & Public Health
Topic Subcategory
Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Infectious Disease (non-vaccine)
Explore Related HEOR by Topic